Immunological characteristics of the effector cells induced by a combination therapy with cyclophosphamide and allogeneic lymphocytes.
A significant inhibition of tumor growth was observed when sarcoma 180 (S180)-bearing ICR strain mice were treated by a combination therapy, with a low dose of cyclophosphamide (CY) and an inoculation of allogeneic lymphocytes collected from C57BL/6 mice. The growth-inhibitory effect was significantly increased by an inoculation of a relatively lower dose of allogeneic lymphocytes (1 x 10(5) cells) and CY. The effector cells induced in the mice treated with CY and allogeneic lymphocytes expressed the Lyt 1.2, Lyt 2.2, IL-2R antigens on their membrane surface and did not express the H2KbDb (donor H-2) antigen, and they showed a specific cytostatic activity against S180 cells. These results strongly suggested that a combination therapy with a low dose of CY with an inoculation of allogeneic lymphocytes augmented an induction of specific cytotoxic T lymphocytes in the tumor-bearing recipient mice.
Sato
S
S
Department of Legal Medicine, School of Medicine, Gunma University, Japan.
Kimura
S
S
Nakamura
T
T
Akuzawa
Y
Y
Kodama
K
K
Furukawa
K
K
Kurashige
S
S
D000818:Animals; D003520:Cyclophosphamide / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D007111:Immunity, Cellular / Q000187:drug effects*; D007167:Immunotherapy; D008213:Lymphocyte Activation; D008212:Lymphocyte Depletion; D017710:Lymphocyte Transfusion; D051379:Mice; D008810:Mice, Inbred C57BL; D012513:Sarcoma, Experimental / Q000628:therapy*; D013154:Spleen / Q000166:cytology; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous
D003520:Cyclophosphamide